Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Veracyte (VCYT) over the last 12 years, with Q1 2025 value amounting to $7000.0.

  • Veracyte's Other Accumulated Expenses fell 9213.48% to $7000.0 in Q1 2025 from the same period last year, while for Mar 2025 it was $7000.0, marking a year-over-year decrease of 9213.48%. This contributed to the annual value of $19000.0 for FY2024, which is 8118.81% down from last year.
  • As of Q1 2025, Veracyte's Other Accumulated Expenses stood at $7000.0, which was down 9213.48% from $19000.0 recorded in Q4 2024.
  • Veracyte's 5-year Other Accumulated Expenses high stood at $241000.0 for Q3 2021, and its period low was $7000.0 during Q1 2025.
  • Its 5-year average for Other Accumulated Expenses is $129800.0, with a median of $119000.0 in 2023.
  • As far as peak fluctuations go, Veracyte's Other Accumulated Expenses crashed by 1948.05% in 2022, and later crashed by 9213.48% in 2025.
  • Veracyte's Other Accumulated Expenses (Quarter) stood at $231000.0 in 2021, then fell by 19.48% to $186000.0 in 2022, then crashed by 45.7% to $101000.0 in 2023, then crashed by 81.19% to $19000.0 in 2024, then plummeted by 63.16% to $7000.0 in 2025.
  • Its Other Accumulated Expenses stands at $7000.0 for Q1 2025, versus $19000.0 for Q4 2024 and $53000.0 for Q3 2024.